Endometriosis Diagnosis and Management in Adolescent Patients and Current Treatment Regimes

Endometriosis disease affects about an estimated number of 176 million women worldwide, which constitutes ~10% of the total female population causing debilitating symptoms of pelvic pain and infertility, thus limiting the quality of reproductive life of an affected woman. Progestins now have became a mainstay of endometriosis suppression, out of which dienogest has been opted as a best option worldwide. Its an expertise literature review with recommendations on the use of dienogest in the context of various clinical considerations when treating endometriosis disease. Experts have reviewed and included those, which they found to be considered most relevant in clinical practices, based on their own clinical experiences. Long-term uses (>15 months) of dienogest for the management of endometriosis is presented, with experts concluding that the efficacy of dienogest must be assessed primarily for its impact on pain and quality of life of a woman. Fertility preservation, avoiding or delaying surgery, and managing the bleeding irregularities occurring because of this medical treatment are also considered here. Counseling women on potential bleeding risks before starting the treatment may be helpful, as the evidences suggest that few of them discontinues the treatment because of this reason outweighing the benefits. Overall, the evidences demonstrate that dienogest offers an effective and tolerable alternative in adjunct to surgery and provids many advantages over combined hormonal contraceptives for the treatment of endometriosis. But its important for all that treatment guidelines must be followed strictly with great care and must be tailored to the woman’s individual needs and their desires.